arrow
S

Sandrine Macé

Houston Methodist
H指数:29
被引数:4,213

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: Dynamics of MRD-negativity in the IMROZ study

Isatuximab,bortezomib,lenalidomide,dexamethasone用于多发性骨髓瘤:IMROZ研究中MRD阴性的动态变化

Blood
IF23.1
2026-03-030
OA
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study

Isatuximab联合化疗用于复发/难治性急性淋巴细胞白血病或急性髓系白血病的儿科患者:ISAKIDS研究

2025-10-300
OAAI
Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

贝卢莫苏迪尔减轻口腔慢性移植物抗宿主病组织炎症和纤维化:一项ROCKstar伴侶研究

2025-05-050
OA
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
2024-10-015
PRE
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

Isatuximab-泊马度胺-地塞米松与泊马度胺-地塞米松在复发和难治性多发性骨髓瘤患者中的比较: 最终总生存分析

2024-02-017
OAAI
Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
2023-10-010
OA
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)
2023-09-271
OAAI
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
LEUKEMIA
IF13.4
2023-06-147
OAAI
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
2023-05-0944
OAAI